SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
3,678.50
-65.50 (-1.75%)
At close: 5:02PM GMT
Stock chart is not supported by your current browser
Previous close3,744.00
Open3,667.00
Bid0.00 x 51000
Ask0.00 x 53800
Day's range3,650.00 - 3,713.00
52-week range3,435.50 - 5,067.00
Volume5,224,379
Avg. volume2,704,773
Market cap33.01B
Beta1.80
PE ratio (TTM)49.38
EPS (TTM)74.50
Earnings date13 Feb 2017 - 17 Feb 2017
Forward dividend & yield0.26 (0.51%)
Ex-dividend date2016-09-08
1y target est69.31
  • Reuters5 days ago

    Tesco, Vodafone keep FTSE afloat

    By Danilo Masoni and Kit Rees MILAN (Reuters) - Britain's top stock index steadied on Tuesday as Tesco (TSCO.L) rallied after it won approval for a takeover and Vodafone (VOD.L) reported strong results, ...

  • Shire Gets Positive CHMP Opinion for Hemophilia A Drug
    Zacks5 days ago

    Shire Gets Positive CHMP Opinion for Hemophilia A Drug

    Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.

  • Poor earnings updates keep European shares at seven-week low
    Reuters6 days ago

    Poor earnings updates keep European shares at seven-week low

    The pan-European STOXX 600 (.STOXX) was 0.7 percent lower at its close, with almost every sector ending in negative territory. France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. Exane BNP Paribas affirmed its underperform rating on EDF.

  • Reuters - UK Focus6 days ago

    Poor earnings updates keep European shares at 7-week low

    France's EDF was the biggest faller on the day, dropping more than 10 percent after lowering its 2018 earnings and cash flow forecasts. This was due to lower than expected power consumption, lower availability of some of its nuclear reactors in early 2018 and a drop in capacity compensation in Britain.

  • GlobeNewswire7 days ago

    CHMP recommends EU marketing authorization for ADYNOVI® for adults and adolescents with Hemophilia A

    CHMP recommends EU marketing authorization for ADYNOVI ® for adults and adolescents with Hemophilia A If approved, ADYNOVI, built on ADVATE ® [Antihemophilic ...

  • Why Motif Bio plc is a growth bargain I’d buy and hold for 25 years
    Fool.co.uk8 days ago

    Why Motif Bio plc is a growth bargain I’d buy and hold for 25 years

    Motif Bio PLC (LON: MTFB) has a bright outlook but growth will take time.

  • GlobeNewswire9 days ago

    Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology

    Shire presentations at ASH 2017 highlight commitment to furthering research and innovation in Hematology and Oncology Lexington, Mass. - November 10, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the leading ...

  • The Only 3 Big Pharma Companies Growing Market Share
    Motley Fool12 days ago

    The Only 3 Big Pharma Companies Growing Market Share

    Most big pharma companies will actually lose market share over the next few years. These three will gain market share -- but in very different ways.

  • GlobeNewswire16 days ago

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   November 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transactions by persons discharging managerial responsibilities   1. Details of the person discharging ...

  • FTSE surges after BoE's 'dovish' hike hits sterling
    Reuters17 days ago

    FTSE surges after BoE's 'dovish' hike hits sterling

    By Danilo Masoni and Helen Reid MILAN/LONDON (Reuters) - Britain's top share index posted its biggest rise in over three months on Thursday after the Bank of England tempered investors' expectations on ...

  • Reuters - UK Focus17 days ago

    BUZZ-Xenetic Biosciences Inc: Soars on deal with Shire's unit

    ** Drug developer's shares up as much as 67.19 pct to $3.7 - stock top pct gainer on Nasdaq, after it says entered agreement to license rights of certain patents related to its drug development platform ...

  • GlobeNewswire18 days ago

    Shire plc : Total voting rights

    Total Voting Rights November 1, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...

  • Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong
    Zacks20 days ago

    Shire (SHPG) Q3 Earnings Beat, Immunology Franchise Strong

    Shire (SHPG) reported better-than-expected third-quarter earnings and also registered strong growth in immunology franchise. Shares were up in response.

  • MarketWatch20 days ago

    Fund manager, analysts make the case for this ‘loathed’ pharma stock

    Irish pharmaceutical giant Shire has seen its shares slump this year, turning in one of the worst performances among United Kingdom-listed blue chips. The bear case may have some cracks in it, however....

  • Reuters23 days ago

    Shire to make genetic disease drug itself to secure supply

    Shire (SHP.L) will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion(£2.67 billion) despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Reuters - UK Focus23 days ago

    Shire to make genetic disease drug itself to secure supply

    LONDON, Oct (Shenzhen: 000069.SZ - news) 27 (Reuters) - Shire (Xetra: S7E.DE - news) will start making a genetic disease medicine itself after it was hit by supply problems, the London-listed firm said on Friday as it reported a sharp rise in profit. "We delivered strong growth this quarter with product sales up 7 percent to $3.5 billion despite a Cinryze supply shortage and a Lialda generic entry," Shire Chief Executive Flemming Ornskov said in a statement. Ornskov said Shire's immunology drugs to treat diseases like Guillain-Barre syndrome performed strongly in the quarter and growth in the franchise it acquired by buying Baxalta (Xetra: 9BX.DE - news) last year rose from a historical rate of 6-8 to 21 percent year to date.

  • Fool.co.uk23 days ago

    One FTSE 100 turnaround stock I’d buy and one I’d sell

    Roland Head looks takes a bold view on two battered FTSE 100 (INDEXFTSE:UKX) stocks.

  • Associated Press23 days ago

    Shire beats 3Q profit forecasts

    On a per-share basis, the Dublin-based company said it had net income of $1.81. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to $3.81 per share. The results ...

  • GlobeNewswire25 days ago

    Shire Receives European Approval for Label Extension of FIRAZYR® (icatibant injection) for the Symptomatic Treatment of Acute HAE Attacks in Paediatric Patients

    Shire Receives European Approval for Label Extension of FIRAZYR ® (icatibant injection) for the Symptomatic Treatment of Acute Hereditary Angioedema (HAE) Attacks in Paediatric Patients FIRAZYR is the ...

  • GlobeNewswire25 days ago

    Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A

    Shire Receives Orphan Drug Designation for Gene Therapy Candidate SHP654 (BAX 888) for the Treatment of Hemophilia A SHP654 investigational new drug (IND) application accepted by the FDA Lexington, MA -  ...

  • Fool.co.uk26 days ago

    2 beaten-up FTSE 100 stocks: is now the time to buy?

    Edward Sheldon looks at two FTSE 100 (INDEXFTSE:UKX) stocks that are way off their highs. Are these stocks now bargains?

  • Shire's New Formulation of Oncaspar Gets CHMP Recommendation
    Zackslast month

    Shire's New Formulation of Oncaspar Gets CHMP Recommendation

    Shire's (SHPG) marketing authorization application for a new (dried) formulation of its leukemia drug, Oncaspar, received CHMP recommendation for approval in EU.

  • Activist fund seeks break-up of £35bn pharma group Shire
    Sky Newslast month

    Activist fund seeks break-up of £35bn pharma group Shire

    A US hedge fund is demanding a string of divestments at the FTSE-100 biotech group Shire (Xetra: S7E.DE - news) , underlining growing interest among activist investors in large European companies. Sky News has learnt that Sachem Head Capital Management is urging the board of Shire, which specialises in treatments for rare diseases and neuroscience products, to explore a sale or spin-off of several of its assets. The move, which has been raised during discussions between the hedge fund and Shire directors in recent months, comes after Sachem Head disclosed during the summer that it had acquired a small stake in the pharmaceuticals group.

  • GlobeNewswirelast month

    Shire plc : New Formulation of ONCASPAR® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL)

    New Formulation of ONCASPAR ® (pegaspargase) Receives Positive CHMP Opinion in Europe for Patients with Acute Lymphoblastic Leukemia (ALL) If approved, lyophilized formulation would offer three times longer ...

  • GlobeNewswirelast month

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   October 5, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company")   Notification of transactions by person discharging managerial responsibilities   1. Details ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes